FormuNova

FormuNova is a preclinical-stage biotechnology company focused on developing innovative drug delivery systems for the treatment of ophthalmic and other chronic diseases. The company utilizes its proprietary Nova-Sustained Release Platform to create long-acting formulations that aim to reduce the frequency of invasive injections, such as intravitreal treatments for retinal diseases. Their lead programs focus on delivering established therapeutic agents like VEGF inhibitors and corticosteroids through advanced nanoparticle and hydrogel technologies. By improving the pharmacokinetic profiles of existing drugs, FormuNova seeks to enhance patient compliance and clinical outcomes in ophthalmology. The company is headquartered in the United States and maintains research operations focused on translational medicine.